Login to Your Account

Advaxis kicks off global strategy in licensing deal with Taiwanese start-up

By Shannon Ellis
Staff Writer

Wednesday, December 18, 2013

SHANGHAI – Advaxis Inc. signed an exclusive licensing agreement with newly minted Global Biopharma Inc. (GBP), of Taiwan, to develop and commercialize ADXS-HPV, an immunotherapy treatment for human papillomavirus (HPV) associated diseases.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription